Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 908-910

  Dervieux, Thierry ^a   Weinblatt, Michael E ^b   Kivitz, Alan ^c   Kremer, Joel M ^d  

^a Exagen Diagnostics Inc   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Altoona Center for Clinical Research   (United States)

^d Center for Rheumatology LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB; METHOTREXATE; METHOTREXATE POLYGLUTAMATE;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTI-TNF; METHOTREXATE; PHARMACOKINETICS; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID;

EID: 84877594377     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202591     Document Type: Article

References (16)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Baert F, Noman M, Vermeire S, et al. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
3. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15.
4. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9. (Pubitemid 44955878)
5. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-52.
6. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53. (Pubitemid 38834038)
7. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. (Pubitemid 28459913)
8. Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classi fication criteria for rheumatoid arthritis: Phase 2 methodological report. Ann Rheum Dis 2010;69:1580-8.
9. Dervieux T, Orentas LD, Marcelletti J, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003;49:1632-41. (Pubitemid 37194217)
10. Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods 2011;373:229-39.
11. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9. (Pubitemid 34620190)
12. Mulleman D, Meric JC, Paintaud G, et al. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 2009;11:R178.
13. Morgan SL, Oster RA, Lee JY, et al. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004;50:3104-11. (Pubitemid 39371985)
14. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322-8. (Pubitemid 28335191)
15. Joseph A, Neff K, Richard J, et al. Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival. J Immunol 2012;189:732-43.
16. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914-5.